Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request ...

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If ...

Researchers have gained new insights into the genetic basis of rye reproduction. They have demonstrated how plants recombine ...

“Dyadic is advancing its transition to ... These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ ...

production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system," issued a press release on October 17, 2025, ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life ...